Genomic Health Inc. (GHDX)

72.70
NASDAQ : Health Technology
Prev Close 72.70
Day Low/High 0.00 / 0.00
52 Wk Low/High 30.04 / 92.18
Avg Volume 409.60K
Exchange NASDAQ
Shares Outstanding 36.12M
Market Cap 2.63B
EPS -0.10
P/E Ratio 142.55
Div & Yield N.A. (N.A)

Latest News

NICE Expands Recommendation For The Oncotype DX Breast Recurrence Score® Test To More Patients With Early-Stage Breast Cancer Within The United Kingdom

NICE Expands Recommendation For The Oncotype DX Breast Recurrence Score® Test To More Patients With Early-Stage Breast Cancer Within The United Kingdom

- Only test recommended based on its ability to predict chemotherapy benefit

Genomic Health To Present At The 37th Annual J.P. Morgan Healthcare Conference

Genomic Health To Present At The 37th Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Dec.

First Week Of January 2019 Options Trading For Genomic Health (GHDX)

First Week Of January 2019 Options Trading For Genomic Health (GHDX)

Investors in Genomic Health Inc saw new options become available this week, for the January 2019 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GHDX options chain for the new January 2019 contracts and identified one put and one call contract of particular interest.

New Analysis Of NSABP Randomized B-20 Study Confirms Patients With Oncotype DX Breast Recurrence Score® Results Greater Than 25 Have Life-saving Substantial Benefit From Chemotherapy, Reinforcing The Conclusions Of The Landmark TAILORx Study

New Analysis Of NSABP Randomized B-20 Study Confirms Patients With Oncotype DX Breast Recurrence Score® Results Greater Than 25 Have Life-saving Substantial Benefit From Chemotherapy, Reinforcing The Conclusions Of The Landmark TAILORx Study

Published Results Underscore Value of Oncotype DX® Test in Identifying Women with Early-stage Breast Cancer Who May Receive Life-saving Benefit from Chemotherapy

Genomic Health Announces Record Revenue And Profit In Third Quarter 2018 Financial Results; Raises Full Year Guidance

Genomic Health Announces Record Revenue And Profit In Third Quarter 2018 Financial Results; Raises Full Year Guidance

Reported $101M in Revenue and Delivered 23 Percent Growth on a Pre-606 Adjusted Revenue Basis

Medicare Establishes Final Local Coverage Determination (LCD) For Use Of The Oncotype DX® AR-V7 Nucleus Detect™ Test In Patients With Metastatic Castrate Resistant Prostate Cancer Effective December 10

Medicare Establishes Final Local Coverage Determination (LCD) For Use Of The Oncotype DX® AR-V7 Nucleus Detect™ Test In Patients With Metastatic Castrate Resistant Prostate Cancer Effective December 10

Medicare coverage supports clinical utility of the Oncotype DX AR-V7 Nucleus Detect test, providing 25,000 Medicare patients with coverage

Genomic Health Announces Multiple Studies Reinforcing Value Of Oncotype DX® Tests In Guiding Treatment For Breast And Prostate Cancer Patients

Genomic Health Announces Multiple Studies Reinforcing Value Of Oncotype DX® Tests In Guiding Treatment For Breast And Prostate Cancer Patients

Studies Presented at ESMO 2018 Congress Underscore Growing Clinical Evidence Across Genomic Health's Test Portfolio

New NCCN Breast Cancer Guidelines Elevate Oncotype DX Breast Recurrence Score® As The Only Preferred Multi-gene Test To Predict Chemotherapy Treatment

New NCCN Breast Cancer Guidelines Elevate Oncotype DX Breast Recurrence Score® As The Only Preferred Multi-gene Test To Predict Chemotherapy Treatment

Updated NCCN Guidelines Underscore the Unique Advantage of the Oncotype DX® Test in Predicting Chemotherapy Benefit

New Published Data And Recent Positive Private Payor Coverage Decisions Underscore Value And Utility Of The Oncotype DX Genomic Prostate Score® (GPS™) Test

New Published Data And Recent Positive Private Payor Coverage Decisions Underscore Value And Utility Of The Oncotype DX Genomic Prostate Score® (GPS™) Test

New Analysis from Unprecedented Study of Patient Medical Records from Large Private U.S. Health Insurer Reconfirms Active Surveillance Increases by 30 Percent in Patients Using GPS™ Test, Improving Adherence to Guideline-based Treatment

Epic Sciences Announces Completion Of $52 Million Series E Financing

Epic Sciences Announces Completion Of $52 Million Series E Financing

Proceeds will be used to advance liquid biopsy tests to predict drug response in cancer patients and to integrate company's No Cell Left Behind platform with electronic medical records and big data analytics

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AJRD, BXP, CARB, CDR, DOC, FTAI, GHDX, GOV, HOME, IKNX, LOCO, NBIX, NYLD.A, RFP, UEIC Downgrades: APU, HY, MFNC, SGMS, TFX Initiations: EEX, SSTI Read on to get TheStreet Quant Ratings' detailed report:

Genomic Health Announces Second Quarter 2018 Financial Results And Reports Recent Business Progress

Genomic Health Announces Second Quarter 2018 Financial Results And Reports Recent Business Progress

Reported Record Revenue of $95.6M and Delivered 14 Percent Growth on a Pre-606 Adjusted Revenue Basis

Genomic Health To Announce Second Quarter 2018 Financial Results And Host Conference Call On Thursday, August 2, 2018

Genomic Health To Announce Second Quarter 2018 Financial Results And Host Conference Call On Thursday, August 2, 2018

REDWOOD CITY, Calif., July 26, 2018 /PRNewswire/ -- Genomic Health, Inc.

First Week Of GHDX August 17th Options Trading

First Week Of GHDX August 17th Options Trading

Investors in Genomic Health Inc saw new options begin trading this week, for the August 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GHDX options chain for the new August 17th contracts and identified one put and one call contract of particular interest.

GHDX Crosses Above Average Analyst Target

GHDX Crosses Above Average Analyst Target

In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $32.28, changing hands for $33.11/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Genomic Health Reaches Analyst Target Price

Genomic Health Reaches Analyst Target Price

In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $32.28, changing hands for $32.73/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Oversold Conditions For Genomic Health (GHDX)

Oversold Conditions For Genomic Health (GHDX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Relative Strength Alert For Genomic Health

Relative Strength Alert For Genomic Health

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

GHDX Crosses Above Average Analyst Target

GHDX Crosses Above Average Analyst Target

In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $31.90, changing hands for $32.15/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

GHDX Crosses Above Average Analyst Target

In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $30.89, changing hands for $32.21/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

GHDX Crosses Above Average Analyst Target

In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $31.05, changing hands for $31.08/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ALLY, CENX, DEL, DK, FWRD, GHDX, GWW, MLNX, QUAD, TSLX, WFM, WIRE Downgrades: AIMC, FTR, TRN Initiations: ACBI Read on to get TheStreet Quant Ratings' detailed report:

TheStreet Quant Rating: B- (Buy)